Skip to main content
High Contrast
|
Reset
-A
A
+A
Notices
|
Media Release
|
Trading Holidays
|
BSEPlus
|
BSE SME
|
Payments to BSE
|
Contact us
|
Careers
|
FeedBack
|
(Indicative Close)
Get Quote
quote options
Equity T+1
Equity T+0
Derivatives
MF/ETFs
Debt/Others
Currency Derivatives
Commodity Derivatives
Electronic Gold Receipts
Hybrid Security
Municipal Bonds
SSE
Menu
Home
About BSE
Investors Relations
Markets
Public Issues/OFS/SGB
Corporates
Members
Investment Advisers
Research Analysts
Investors
Market Data Products
Corporates
Get Listed
Get Listed
Listing Instruments
Equity Shares
Debt
IDR
Non-Convertible Redeemable Pref. Shares
Perpetual Non-Cumulative Preference Shares
Listing on SME platform
Innovators Growth Platform (IGP)
BSE Hi-Tech
Mutual Funds / ETF
Alternate Investment Fund
InviTs
REITs
Commercial Paper (CP)
Benefits of Listing
Listing Fees
Listing Regulations & Agreement
Master Checklist for Listing
Direct Listing (without IPO)
BSEPSU.com
Checklist for Accredited Investors
Corporate Filings
Corporate Filings
Corporate Announcements
Corporate Actions
Financial Results
Board Meetings
Cancelled / Revised
Shareholders Meetings
Voting Results
Result Calendar
Shareholding Patterns
Corporate Governance Scorecard
Corporate Governance
Offer Documents
Schemes under Regulation 37
Sustainability Reports
Historical Annual Reports
XBRL Filings
XBRL to Excel converter
XBRL
Disclosures Submitted by Company
Insider Trading 1992
Insider Trading 2015
SAST
Pledge
Reasons for Encumbrance
SAST Annual Disclosures
Consolidated - Pledge data
PIT Trading Plan
System Based Disclosures
Insider Trading 2015
SAST
Pledge
SAST Annual Disclosures
Continual Disclosure under Insider Trading Regulation (w.e.f. October 01, 2020)
Information Memorandum
QIP Equity
Institutional Placement – InvITs
Institutional Placement – REIT
Scheme of Arrangement
Companies listed under Direct Listing
Revocation
PIT Mutual Funds
Off market transaction – Reg 5D(1) (i)
Trading Plan – Reg 5D(1)(iv)
Quarterly Disclosures - Reg 5E (1) – RTA
Event based disclosures – Reg 5E (2) – RTA
UPSI declaration
Compliances and Other Info
Compliance
Listing Centre
Circulars to Listed Companies
SEBI Clarifications on Insider Trading
Downloads
Compliance Calender
Revocation of Securities
SOP Non Compliance under LODR
Companies Eligible for Offer for Sale
Rating Action by CRA’s
FAQs on Listing
FAQs on Business Responsibility Report
Compulsory Delisting
Companies Suspended for more than 7 years
Companies under IBC
Non Payment of Listing Fee Dues
CRA - Sharp Rating Actions
Non-Compliance of DN Database
Master circular for Listing Compliance
ESG Rating
Corporate and Other Info
Delisted companies
Companies with name change
Buy back
Industry classification
Listed Securities
Corporate Governance Scorecard
Independent Directors Databank portal
Corporate Group Repository
Historical Data
Compliance Status for Companies
Historical Compliance
SEBI order on MPS
SEBI relaxation for MPS
Company Mergers
Corporate Announcement
Security Code :
526953
Company :
VENUSREM
Venus Remedies spreads its wings in GCC. First Indian company to receive GCC approval to market its Oncology & Carbapenem range of products in Gulf
Exchange Disseminated Time
Venus Remedies Ltd has informed BSE regarding "Venus Remedies spreads its wings in GCC. First Indian company to receive GCC approval to market its Oncology & Carbapenem range of products in Gulf"
Announcement:
"The Company has once again achieved a very significant landmark in its list of achievements. It has now been awarded the company registration from GCC (Gulf Cooperation Council). This approval holds significance and is prestigious as such registrations are obtained by the manufacturing facilities which meet world class standards and where quality is of the prime essence.
With this prestigious grant Venus Remedies will strengthen its footmark in GCC pharmaceutical market and will enhance its revenues by 10% per cent by 2013.
Venus Remedies is already present in different countries of middle east with its products in oncology,
carbapenem/cephalosprin segment. With this Company registration certificate, Venus Remedies Limited now features as the first Indian Company having received the GCC approval to market its Oncology & Carbapenem range of products in all the GCC countries comprising of Saudi Arabia, UAE, Kuwait, Qatar, Bahrain, and Oman.
The GCC combined pharmaceutical market is worth more than US$8 billion growing at CAGR of 8%, which offers tremendous opportunities to the Company to enter both in the private and public segments of the market. "I attribute this success to the five years of dedicated hard work of the VRL team" added Mr. Chaudhary.
Combined GCC tender of the states alone accounts of mare than US$900 million and the Company has ambitious plans to participate in this institution sales.
Earlier, Venus was also awarded Saudi Arabia FDA GMP which gave it the opportunity to enter in the Saudi Arabian market alone worth of $ 3.5 billion."
Disclaimer
Back To Announcements